Status:
COMPLETED
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will determine the maximum tolerated dose and pharmacokinetic profile of R1507 in patients with metastatic or locally advanced malignant solid tumors, non-Hodgkin's lymphoma or Hodgkin's ly...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- solid neoplasm, non-Hodgkin's lymphoma or Hodgkin's lymphoma;
- metastatic or locally advanced disease, not curable by any currently available treatment.
Exclusion
- severe, uncontrolled systemic disease;
- patients who require treatment with glucocorticoids or immunosuppressive treatment within last 6 months;
- patients with diabetes mellitus.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00400361
Start Date
April 1 2006
End Date
April 1 2011
Last Update
November 2 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Aurora, Colorado, United States, 80045
2
New Brunswick, New Jersey, United States, 08901
3
Houston, Texas, United States, 77030